Since the beginning of 2022, 24 pharmaceutical stocks have risen by more than 20%

[Pharmaceutical Network Pharmaceutical Stock Market] Since the beginning of 2022, the pharmaceutical industry has fallen by more than 18%, but some individual stocks have grown against the tre.
According to the statistics of Flush, from January 4 to June 22, 2022, at least 24 of the 451 pharmaceutical and biological stocks rose by more than 20%, mainly focusing on traditional Chinese medicine, chemical medicine, raw materials, medical equipment, pharmaceutical business and other subdivisio.
In terms of individual stocks, Shanghai Yizhong has the highest increase, with an increase of 3224% in the range, and Xinhua Pharmaceutical with an increase of more than 100% in the range, with an increase of 1516%; the range of increase between 50% and 100% includes Dali Pharmaceutical, China Medicine, Haichen Pharmaceutical, China Resources Shuanghe, Tuoxin Pharmaceutic.
 Since the beginning of 2022, 24 pharmaceutical stocks have risen by more than 20% (Source: Pharmaceutical Network) Shanghai Yizhong: The range has increased by more than 300% Shanghai Yizhong has increased by more than 300%, and has performed we.
As of the close of June 21, Shanghai Yizhong quoted 1850 yuan, with an amplitude of 47% and a turnover rate of 4
The stock has been stronger than the broader market in the past month, with a cumulative turnover rate of over 30% in the past 5 da.
The company recently issued a stock price change announcement saying that the company's core product, paclitaxel polymer micelles for injection, was approved on October 26, 2021, and the product is still in the early stages of listing; the company's current annual production capacity of 1 million is the theoretical production capacity, and the production process , Affected by factors such as periodic verification of equipment, the actual production capacity is lower than the theoretical design capaci.
According to public information, Shanghai Yizhong is committed to the development of innovative drugs and related produc.
It is a high-tech pharmaceutical company integrating R&D, production and commercializati.
The company's operating income mainly comes from the sales of paclitaxel polymer micelles for injecti.

According to the first quarterly report of 2022, the company achieved operating income of 334 million yuan and net profit of 374 million yuan from January to Mar.
Xinhua Pharma: Range rose over 155% Xinhua Pharma's share price rose over 155% from January 4 to June 2 The stock is also a stock that has outperformed the broader market in the past month, with a cumulative turnover rate of over 30% in the past 5 da.
As of the close on June 21, the stock reported 200 yuan, with an amplitude of 91% and a turnover rate of 24
On June 20, the stock just hit its daily lim.
In terms of news, recent market rumors said that Azvudine supplemented the data for the third phase, and the market once again looked forward to the approval progress of Azvudi.
However, the rumor has not yet been confirm.

It is reported that Xinhua Pharma and Real Bio have previously signed a "Strategic Cooperation Agreement", and Real Bio agreed that Xinhua Pharma will be the product manufacturer and distributor of Azvudine and other products it owns in China and other countries agreed by both parti.

The company’s first quarterly report this year shows that in the first quarter, the main revenue was 831 billion yuan, up 57% year-on-year; the net profit attributable to the parent was 109 million yuan, up 2% year-on-year; the non-net profit was 105 million yuan, up 92% year-on-year; the debt ratio was 426 %, the investment income is 147,000 yuan, the financial cost is 12,269,600 yuan, and the gross profit rate is 23
According to the data, the main business of Xinhua Pharmaceutical is to develop, manufacture and sell chemical raw materials, pharmaceutical preparations, chemicals and other produc.

Dali Pharmaceutical: Range rose by over 83% Dali Pharmaceutical is an outstanding Chinese medicine sto.

The stock has outperformed the broader market in the past month, and the cumulative turnover rate in the past 5 days has exceeded 3
As of the close on June 21, the closing price was 191 yuan, with an amplitude of 149% and a turnover rate of 18Recently, the company issued an announcement on abnormal fluctuations in stock trading, stating that the deviation of the closing price of the company's stocks on June 15, 2022 and June 16, 2022 for two consecutive trading days has accumulated by 209%, which belongs to abnormal fluctuations in stock tradi.

After the company's self-inspection and written consultation with the controlling shareholder and actual controller, as of the disclosure date of this announcement, there is no material information that should be disclosed but has not been disclos.

According to the first quarterly report of 2022, the company’s accumulated operating income was 38167 million yuan, a year-on-year decrease of 174%; the net profit attributable to shareholders of the listed company was a loss of 2075 million yuan, which turned from profit to loss compared with the same period last ye.

The income is -0146 yu.

According to the data, Dali Pharmaceutical's main business is the production and sales of Chinese and Western medicine injectio.

Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.

 Click to enter the exhibition